Earn CME: https://naccme.com/program/7311
In this presentation from the ‘FLT3 Targets in AML: Evaluating Emerging Clinical Data and Implications on Current Practice symposium, Dr. Gail J. Roboz discusses the correct targets for patients with newly diagnosed acute myeloid leukemia (AML).
© 2018 Imedex, an HMP Company